Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0NIGOF
ADC Name	PODO447-ADC
Synonyms	PODO447-Vedotin; PODO447 ADC Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Ovarian cancer [ICD11:2C73] Investigative Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	PODO447		Antibody Info
Antigen Name	Podocalyxin (PODXL)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Pancreas cancer PDX model (PDX: MIA PaCa-2)

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 56)	High PODXL expression (PODXL+++)
Method Description	MIA PaCa-2 (1x10⁶) or OV3331 (1x10⁶) cells were injected subcutaneously into the right flank of NSG or nude mice. Tumor dimensions were measured twice a week and tumor volumes (cm³) were calculated by. Once tumors reached 0.15cm³, mice were treated with either PODO447- or palivizumab-Vedotin at concentrations ranging from 4 2 mg/kg. ADC treatments were administered intravenously every 4 days. Click to Show/Hide
In Vivo Model	Pancreas cancer PDX model (PDX: MIA PaCa-2)

References

Ref 1	Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models. Front Oncol. 2022 May 4;12:856424.